Profil bibliographique

Ntombizonta Ignatia Phewa

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

3Publications signalées
2Citations signalées
0Affiliations récentes

Les domaines associés

HIV/AIDS drug development and treatmentHIV-related health complications and treatmentsHIV/AIDS Research and InterventionsVirus-based gene therapy research

Les publications récentes

Accès ouvert 2026 article OpenAlex

Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, Cissy M Kityo, Diana Louis Anena et autres

BACKGROUND: Adolescents living with HIV have poorer treatment outcomes than other age groups and might benefit from long-acting-injectable (LAI) antiretroviral therapy (ART). We evaluated efficacy and safety of LAI cabotegravir-rilpivirine compared with daily oral ART in adolescents living with HIV with virological …

Zimbabwe, gb, Ouganda, Kenya, Afrique du Sud, it, nl (code pays fourni par la source)

0 citations The Lancet
Accès ouvert 2026 article OpenAlex

Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial

Adeodata Kekitiinwa, Angus C. Jennings, Mutsa Bwakura-Dangarembizi, Cissy M Kityo et autres

BACKGROUND: Short-cycle antiretroviral therapy (ART), comprising 5 days on and 2 days off treatment, offers the potential for ART-free weekends, reduced toxicity, and improved quality of life for adolescents living with HIV, who typically have worse treatment outcomes than other age groups. …

Ouganda, gb, Zimbabwe, Kenya, Afrique du Sud, it, nl (code pays fourni par la source)

0 citations The Lancet HIV
Accès ouvert 2026 article OpenAlex

Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu et autres

BACKGROUND: Alternatives to daily oral antiretroviral therapy (ART) are important for adolescents with HIV (AHIV) to improve adherence and outcomes. Long-Acting-injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) has demonstrated excellent efficacy and safety and strong patient preference in adults. METHODS: LATA is an ongoing randomised, …

Ouganda, gb, Kenya, Zimbabwe, Afrique du Sud, it, nl (code pays fourni par la source)

2 citations Contemporary Clinical Trials
Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.